TRI-611, an Oral Drug Tested in Advanced ALK-Positive Lung Cancer
Tests TRI-611 for safety and dosing in adults with ALK-positive non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Key facts
- Where
- A Coruña, Barcelona, Logroño, and Madrid, SpainSee the 6 sites
- Phase
- Phase 1/2
Where in Spain
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpainNot yet recruiting
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
- Micancer Center S.L.P.Barcelona, SpainNot yet recruiting
- Hospital San PedroLogroño, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- TRIANA Biomedicines, Inc.
- Trial code
- NCT07491497EU 2025-524418-27-00
- Record updated
- 5 November 2026
- Original description
The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC.Read full original descriptionShow less
A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC
The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC.
The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received.
In this study participants will:
* Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not progressing * Visit the clinic approximately seven times in the first 3 months and then just once at the start of each 28-day cycle thereafter * Keep a diary of each time they take the study medication
Inclusion: Pathologically confirmed diagnosis of ALK-positive non-small cell lung cancer (NSCLC); Measurable disease per RECIST v1.1; Adequate bone marrow reserve and organ function; Part 1: prior treatment with 2 to 3 ALK TKIs [in US only: '2 or more ALK TKIs'], prior treatment with lorlatinib is required but must not have been in the first line; Part 2 Cohort M1: prior treatment with 2 to 3 ALK TKIs, prior treatment with lorlatinib is required but must not have been in the first line, prior treatment with neladalkib is excluded; Part 2 Cohort M2: prior treatment with more than 3 ALK TKIs, prior treatment with lorlatinib and neladalkib is required but neither may have been in the first line; Part 2 Cohort M3: participants without prior ALK TKI treatment.
Exclusion: Ongoing treatment with another anticancer treatment or investigational agent; Major surgery within 4 weeks of receiving the first dose of TRI-611; Participant's cancer has any additional driver alterations known to be a mechanism of resistance to ALK TKIs; For participants with central nervous system (CNS) metastases or spinal cord compression, they must not be associated with progressive neurological symptoms or require increasing doses of corticosteroids to control the CNS disease; Known allergy/hypersensitivity to TRI-611 or any of its ingredients.